Docetaxel treatment in the elderly patient with hormone refractory prostate cancer.

Research output: Contribution to journalReview article

Abstract

Docetaxel is an anti-microtubular agent in the family of the taxanes, now FDA approved as first line chemotherapy for the treatment of hormone refractory metastatic prostate cancer. Recent data from two large randomized Phase III trials showed a survival advantage in hormone refractory prostate cancer patients treated with docetaxel. This discovery changed the perceptions about utilization of chemotherapy for this devastating disease and introduced a new paradigm/standard of care treatment for this patient population. The management of elderly patients with metastatic prostate cancer is an important issue because according to data from the Surveillance, Epidemiology, and End Results (SEER) program, the American Cancer Society, and the United Nations, the incidence of prostate cancer in elderly men is expected to increase since people are living longer. In this paper we will review the results of trials evaluating docetaxel in hormone refractory prostate cancer and the implications of these trials as they relate to diagnosis and management of this disease in the elderly man.

Original languageEnglish (US)
Pages (from-to)555-560
Number of pages6
JournalClinical interventions in aging
Volume2
Issue number4
StatePublished - 2007

ASJC Scopus subject areas

  • Geriatrics and Gerontology

Fingerprint Dive into the research topics of 'Docetaxel treatment in the elderly patient with hormone refractory prostate cancer.'. Together they form a unique fingerprint.

  • Cite this